Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Urofollitropin
Drug ID BADD_D02319
Description Urofollitropin is a urinary-derived follicle-stimulating hormone (FSH) that is extracted and purified from human urine samples. It consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. The alpha subunit is glycosylated at Asn 51 and Asn 78 while the beta subunit is glycosylated at Asn 7 and Asn 24. Urofollitropin is typically used injected subcutaneously in combination with human chorionic gonadotropin (hCG) to induce ovulation. Urofollitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).
Indications and Usage For treatment of female infertility
Marketing Status approved; vet_approved
ATC Code G03GA04
DrugBank ID DB00094
KEGG ID D06269
MeSH ID D050477
PubChem ID 62819
TTD Drug ID D02SBQ
NDC Product Code 76403-5002; 71052-066; 76403-5001
UNII W9BB98U6HP
Synonyms Urofollitropin | Follicle-Stimulating Hormone, Human Urine | Follicle Stimulating Hormone, Human Urine | Human FSH, Urinary | Urinary Human FSH | Fertinex | Metrodin | Neo Fertinorm | Metrodin HP | Metrodin High Purity | High Purity, Metrodin | Bravelle | Follitrin
Chemical Information
Molecular Formula C42H65N11O12S2
CAS Registry Number 26995-91-5
SMILES CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3C CCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Developmental delay19.07.05.003; 08.01.03.037--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug abuse19.07.06.010--Not Available
Dry skin23.03.03.001--
Dysarthria19.19.03.001; 17.02.08.001--
Dysmenorrhoea21.01.01.002--
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.11.05.003--
Dysuria20.02.02.002--
Ectopic pregnancy18.02.02.002--Not Available
Eczema23.03.04.006--
Embolism venous24.01.01.003--Not Available
Encephalopathy17.13.02.001--
Endocrine disorder05.09.01.001--Not Available
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Exomphalos07.16.03.002; 03.04.07.001--Not Available
Eye disorder06.08.03.001--Not Available
Face oedema08.01.07.003; 23.04.01.004; 10.01.05.002--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Fungal infection11.03.05.001--Not Available
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Genital candidiasis21.10.03.001; 11.03.03.002--Not Available
Genital herpes11.05.02.012; 21.10.03.008--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 9 Pages